Drug Profile


Alternative Names: Glinsuna; Glufast; KAD-1229; Kuai ruo tuo; S 21403

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Aichi Gakuin University; Eisai Co Ltd; Elixir Pharmaceuticals; Hikma Pharmaceuticals; JW Pharmaceutical; Kissei Pharmaceutical; Orient Europharma; Takeda; USV
  • Class Amides; Antihyperglycaemics; Butyric acids; Isoindoles; Small molecules
  • Mechanism of Action Insulinotropin agonists; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 22 May 2017 Aichi Medical University School of Medicine and Kissei Pharmaceutical complete a clinical trial in Type-2 diabetes mellitus in Japan (UMIN000019833)
  • 15 Dec 2016 Biomarkers information updated
  • 17 Jun 2016 Launched for Type-2 diabetes mellitus in Japan (PO; Fast dissolve)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top